Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases
- PMID: 16492721
- DOI: 10.1093/jac/dkl035
Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases
Abstract
Objectives: Extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli have been increasingly recognized in the community. The aim of this study was to determine the prevalence, types of ESBLs and risk factors for community-onset ESBL-producing E. coli in urinary tract infections (UTIs).
Methods: Adults with community-onset UTIs due to ESBL-producing E. coli (cases) and non-ESBL-producing E. coli (controls) were identified through records of the clinical microbiology laboratory of the hospital. Two different periods were studied: from January 2000 to January 2001 and from October to December 2003. Controls were matched in a 3:1 ratio to case patients according to age, sex, date of isolation and residence in a long-term care facility. Potential risk factors were recorded. Isoelectric focusing as well as PCR and DNA sequencing were used to characterize the bla(TEM), bla(SHV) and bla(CTX-M) genes. A possible clonal relationship among the strains was determined by repetitive extragenic palindromic sequence PCR.
Results: The prevalence of infection due to ESBL-producing E. coli increased from 0.47% in 2000 to 1.7% in 2003 (P < 0.001). Community-onset ESBL-producing E. coli infection shifted from 50% in the first period to 79.5% in 2003 (P < 0.001). Nineteen cases and 55 matched controls of community-onset ESBL-producing E. coli UTI were included. ESBL-producing E. coli strains were clonally unrelated. On univariate analysis, genitourinary pathology (P < 0.03), previous bacterial infection (P = 0.01), intravenous antibiotic treatment (P = 0.01), hospitalization in the previous 12 months (P = 0.04) and previous exposure to oral second-generation cephalosporins (P < 0.05) were associated with community-onset infection due to ESBL-producing E. coli. In our regression model, only previous exposure to second-generation cephalosporins was strongly associated with E. coli harbouring ESBLs (OR, 21.42; CI 95%, 5.38-85.22; P < 0.05). In the first period, only TEM- and SHV-derived ESBLs were identified. The enzymes were characterized as members of the TEM group (60%), SHV group (16%) and CTX-M group (24%).
Conclusions: We detected a marked increase in infections due to ESBL-producing E. coli, especially in the community, in the periods studied. Only previous exposure to the oxyimino cephalosporin cefuroxime, and not to ciprofloxacin, aminoglycosides or third-generation cephalosporins, was predictive of an ESBL-producing E. coli community-onset infection in our area. The emergence of the CTX-M type of beta-lactamase in E. coli follows closely the spread of ESBLs in community isolates.
Similar articles
-
Escherichia coli producing SHV-type extended-spectrum beta-lactamase is a significant cause of community-acquired infection.J Antimicrob Chemother. 2009 Apr;63(4):781-4. doi: 10.1093/jac/dkp028. Epub 2009 Feb 17. J Antimicrob Chemother. 2009. PMID: 19223299
-
Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections.Clin Microbiol Infect. 2010 Feb;16(2):147-51. doi: 10.1111/j.1469-0691.2009.02941.x. Epub 2009 Aug 18. Clin Microbiol Infect. 2010. PMID: 19689464
-
Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study.Am J Infect Control. 2007 Nov;35(9):606-12. doi: 10.1016/j.ajic.2007.05.008. Am J Infect Control. 2007. PMID: 17980240
-
Addressing the challenge of extended-spectrum beta-lactamases.Curr Opin Investig Drugs. 2009 Feb;10(2):172-80. Curr Opin Investig Drugs. 2009. PMID: 19197795 Review.
-
Extended-spectrum beta-lactamases in ambulatory care: a clinical perspective.Clin Microbiol Infect. 2008 Jan;14 Suppl 1:104-10. doi: 10.1111/j.1469-0691.2007.01866.x. Clin Microbiol Infect. 2008. PMID: 18154533 Review.
Cited by
-
Extended-spectrum β-lactamase-producing Enterobacteriaceae in Cameroonian hospitals.Eur J Clin Microbiol Infect Dis. 2013 Jan;32(1):79-87. doi: 10.1007/s10096-012-1717-4. Epub 2012 Aug 11. Eur J Clin Microbiol Infect Dis. 2013. PMID: 22886058
-
Mechanisms of Resistance in Gram-Negative Urinary Pathogens: From Country-Specific Molecular Insights to Global Clinical Relevance.Diagnostics (Basel). 2021 Apr 28;11(5):800. doi: 10.3390/diagnostics11050800. Diagnostics (Basel). 2021. PMID: 33925181 Free PMC article. Review.
-
Prevalence and Predictors of Multi-Drug Resistant Organisms Among Ambulatory Cancer Patients with Urinary Tract Infections.Infect Drug Resist. 2023 Feb 3;16:747-753. doi: 10.2147/IDR.S388680. eCollection 2023. Infect Drug Resist. 2023. PMID: 36760782 Free PMC article.
-
Risks factors for infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care university hospital in Switzerland.Infection. 2010 Feb;38(1):33-40. doi: 10.1007/s15010-009-9207-z. Epub 2010 Jan 27. Infection. 2010. PMID: 20108162
-
Risk Factors of Extended-Spectrum Beta-Lactamases-Producing Escherichia coli Community Acquired Urinary Tract Infections: A Systematic Review.Infect Drug Resist. 2020 Nov 3;13:3945-3955. doi: 10.2147/IDR.S269033. eCollection 2020. Infect Drug Resist. 2020. PMID: 33177845 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical